Press release

DSM and Roquette to open commercial scale bio-based succinic acid plant in 2012

Heerlen, NL, 09 May 2011 09:15 CEST

Royal DSM, the global Life Sciences and Materials Sciences company, and the French starch and starch derivatives company Roquette Frères today announce that they will build a commercial scale plant for the production of bio-based succinic acid, the first non-fossil feedstock derived chemical building block that allows customers in the chemical industry to choose a bio-based alternative with a lower eco-footprint for a broad range of applications, from packaging to footwear.

With a capacity of about 10 kilotons per year, the plant will be Europe’s largest bio-based succinic acid facility. It is expected to come on stream in H2 2012 and will be built on the premises of Roquette in Cassano Spinola (Italy). Financial details of the investment will not be disclosed.

Succinic acid is a chemical building block used in the manufacture of polymers, resins, food and pharmaceuticals among other products. Bio-based succinic acid, a renewable and versatile chemical building block, is an alternative to petroleum-derived chemical building blocks such as adipic acid and 1.4-butanediol. As a result of price competiveness and its renewable nature, bio-based succinic acid is addressing a larger market than fossil feedstock based succinic acid.

The commercial scale bio-based succinic acid plant is another important step in the successful cooperation between DSM and Roquette that started in 2008. Early 2010 DSM and Roquette opened a demonstration plant in Lestrem (France), which has been running at full capacity. In 2010 DSM and Roquette also announced their intention to establish a joint venture (which will be carrying out business under the name Reverdia) for their cooperation, subject to regulatory approval.

The initial feedback from the market is very encouraging and proves that DSM and Roquette’s choice to invest in bio-renewable alternatives for fossil feedstocks by using biotechnological routes is starting to pay off. In case the market develops as DSM and Roquette expect an even larger facility will be considered in the future.

Rob van Leen, Chief Innovation Officer of DSM, commented: “The time is right to capitalize on the tremendous progress we have made together with Roquette in the last two years. Our proprietary yeast-based fermentation process not only allows cost effective production; it also eliminates salt waste and other by-products and thus improves the overall eco-footprint of end-products. This bio-based chemical building block is a substitute for various fossil feedstock derived monomers and proves that the bio-based economy is no longer a distant prospect.”

To optimally combine its competences in Life Sciences and Materials Sciences, DSM has set up Emerging Business Areas, including DSM Bio-based Products & Services and DSM Biomedical, for which ambitious growth perspectives have been defined including an aspiration to achieve more than € 1 billion in sales in 2020.

Jean-Bernard Leleu, Deputy CEO and RID Director of Roquette, commented: “We are very encouraged with the development efforts in several new applications and are receiving favorable feedback from customers who have sampled ton quantities from our demonstration plant in Lestrem. The new plant in Italy will allow customers in Europe, North America and Asia to make larger volume commitments to their customers.”

The new commercial production facility in Italy will be producing fermentation based bio-succinic acid. The proprietary yeast-based fermentation process, which operates at a much lower pH than competing processes, allows succinic acid to be produced with a significantly higher energy efficiency compared to the traditional method. It is also one of the first bio-based processes that sequesters carbon dioxide in the production process.

The new production facility will for the time being use starch derivatives as feedstock. In the longer term the aspiration is to switch to second generation feedstock (cellulosic biomass).

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420

Dave Huizing

Vice President Investor Relations
+31 45 578 2864

Media Relations

+31 45 578 2420

Investor Relations

+31 45 578 2864